AbbVie Inc. (ABBV) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-29

Key Insights

AbbVie announced Q1 2026 financial results on April 29, 2026, with the press release furnished as Exhibit 99.1 to this 8-K filing for investor review.
The filing indicates AbbVie has multiple senior notes outstanding across different maturity dates (2027-2031), demonstrating an active debt management strategy with varying coupon rates from 0.750% to 2.625%.
The 8-K was signed by Scott T. Reents, Executive Vice President and Chief Financial Officer, indicating routine quarterly earnings disclosure rather than a material corporate event.
This is a standard Item 2.02 disclosure (Results of Operations and Financial Condition) with no indication of material agreements, leadership changes, or unusual business developments that would typically drive significant market impact.

Want the newest filings?

This analysis covers the filing from 2026-04-29. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-01-07

AbbVie expects to incur $1.3 billion in acquired IPR&D and milestones expense in Q4 2025, which will negatively impact both GAAP and adjusted non-GAAP earnings per share.
AbbVie has updated its full-year 2025 adjusted diluted EPS guidance to $9.90 - $9.94, factoring in the Q4 2025 acquired IPR&D and milestones expense.
AbbVie's Q4 2025 adjusted diluted EPS guidance range is now $2.61 - $2.65, including the impact of the acquired IPR&D and milestones expense.

Other reports for AbbVie Inc.

Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.